Study Title

novartis

A Post Marketing Surveillance on Lutathera® (Lutetium (177Lu) Oxodotreotide, 177Lu-DOTA0-Tyr3-Octreotate) in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) in Korea

Study Details

Description:

This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.

Sponsor:

Novartis

Contacts:

Novartis Pharmaceuticals

novartis.email@novartis.com

+41613241111

Patient Education

Patient Education Not Yet Provided

Publications

Publications Not Yet Provided

Locations

Not yet provided. Contact Novartis Pharmaceuticals for more information.

+41613241111

novartis.email@novartis.com

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468